US drug reimbursement moving toward differentiated, cost-saving therapeutics
This article was originally published in Scrip
Executive Summary
Reimbursement for pricey prescription drugs from government and private payers, with or with US Supreme Court approval of the 2010 health care reform law, will require patient and physician support and an emphasis on health care cost savings going forward.